Table 1.
Summary of findings (SoF) table for outcomes of benefit.
| Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | N. of patients | Effect | Certainty | ||
|---|---|---|---|---|---|---|---|---|---|
| PMRT | no PMRT | Relative (95% CI) | Absolute (95% CI) | ||||||
| OS (Shim, Int J Radiation Oncol Biol Phys 2014) (follow-up: median 59 months; assessed with: events) | |||||||||
| Observational | Not serious | Not serious | Seriousa | Seriousb | 5-years OS: RT: 93.3% vs no RT 89.9% (p = 0.443) | Very low | |||
| OS (Liu, Oncotarget, 2015) (follow-up: median 56 months; assessed with: HR) | |||||||||
| Observational | Not serious | Not serious | Seriousc | Seriousd | HR for RT: 0.82 (0.63–1.068) SUB-GROUP ANALYSIS: 5-years OS IIIB-IIIC: RT 79.3% vs no RT 71.2% (p = 0.027); 5-years OS T3-T4: RT: 82.6% vs no RT 76.6% (p = 0.025) |
Very low | |||
| OS (Cho, Clinical Breast Cancer, 2019) (follow-up median 79 months) | |||||||||
| Observational | Not serious | Not serious | Seriousa | Seriousd | HR for RT: 0.350 (0.096–1.272) | Very low | |||
| OS (Kantor, J Surg Oncol, 2017) (follow-up: median 69 months; assessed with: HR) | |||||||||
| Observational | Seriouse | Not serious | Not serious | Not serious | 5-years OS: RT 92.9% vs no RT 83% (p = 0.441) | Very low | |||
| DFS (Shim, Int J Radiation Oncol Biol Phys 2014) (follow-up: median 59 months; assessed with: KM) | |||||||||
| Observational | Not serious | Not serious | Seriousa | Seriousb | 5-years DFS: RT 91.2% vs no RT 83% (p = 0.441) | Very low | |||
| DFS (Cho, Clinical Breast Cancer, 2019) (follow-up median 79 months; assessed with: HR) | |||||||||
| Observational | Not serious | Not serious | Seriousa | Seriousd | HR: 0.561 (0.249–1.264) | Very low | |||
| LRRFS (Shim, Int J Radiation Oncol Biol Phys 2014) | |||||||||
| Observational | Not serious | Not serious | Seriousa | Seriousb | 5-years LRRFS: RT 98.1% vs no RT 92.3% (p = 0.148) | Very low | |||
| LRRFS (Cho, Clinical Breast Cancer, 2019) (follow-up median 79 months; assessed with: HR) | |||||||||
| Observational | Not serious | Not serious | Seriousa | Seriousd | HR: 0.310 (0.148–1.833) | Very low | |||
Abbreviations: RT: radiotherapy; OS: overall survival; DFS: disease free survival; LRRFS: loco-regional recurrence-free; HR: hazard ratio; CI: confidence interval; RR: risk ratio; PST: preoperative chemotherapy.
Explanations.
a
Indirectness for population, included both cN1 and cN2 diagnosis downstaged to ypN0 after PST.
b
Small population.
c
Indirectness for population, included both in Stage II and III.
d
CI both included effect and no effect.
e
Possible selection bias due to a sub-group analysis of large database.